NeuroPace (NPCE) Preferred Stock Liabilities (2020 - 2021)
NeuroPace (NPCE) posted Preferred Stock Liabilities of $141.4 million for Q1 2021, little changed on a QoQ basis from $141.4 million in Q4 2020, and up 92.23% year-over-year from $73.6 million in Q1 2020.
Powered by 
Analysis
NeuroPace (NPCE) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
NeuroPace has reported Preferred Stock Liabilities for 2 years, with the latest figure at $141.4 million in Q1 2021.
- On a quarterly basis, Preferred Stock Liabilities rose 92.23% year-over-year to $141.4 million in Q1 2021; TTM through Mar 2021 was $141.4 million, a 92.23% increase from a year earlier, with the FY2020 full-year figure at $141.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $141.4 million for Q1 2021 at NeuroPace, roughly flat from $141.4 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $141.4 million in Q3 2020, with the low at $73.5 million in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | - |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | - |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | - |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | - |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | - |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | - |
| 10 | NeuroPace | 493.15 Mn | 441.45 Mn | 18.91 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2021 | 141.42 Mn |
| Dec 31, 2020 | 141.42 Mn |
| Sep 30, 2020 | 141.42 Mn |
| Jun 30, 2020 | 73.45 Mn |
| Mar 31, 2020 | 73.57 Mn |